Skip to content
Screener

Spyre Therapeutics, Inc. SYRE Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue-
EPS-$0.15Beat by $0.53
EPS estimate-$0.68

Next report

Nov 3, 2026 (in 2 months)
EPS estimate-$0.80

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$56.9M-2.7%
Net income-$11.2M+83.8%
EPS (diluted)-$0.15+89.0%

Balance sheet

See full
Cash & equivalents$64.9M-9.3%
Total equity$455.1M+39.0%
Total assets$504.6M+19.8%

Cash flow

See full
Operating cash flow-$37.1M-26.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.01B-32.4%

Returns & leverage

See full
Return on equity-38.1%—
Current ratio10.9×+3.6×

Segments

By segment

See full
Reportable Segment-—

FAQ

When did Spyre Therapeutics, Inc. report Q3 2025 earnings?
Spyre Therapeutics, Inc. (SYRE) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Spyre Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Spyre Therapeutics, Inc. reported revenue of - and eps of $-0.15 for Q3 2025.
Did Spyre Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.68 by $0.53.
How did Spyre Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 89.0% from $-1.36.
Where can I find Spyre Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001636282-25-000104) and the 10-Q periodic report (0001636282-25-000102) directly on SEC EDGAR. The filing index links above go to sec.gov.